Latest News and Press Releases
Want to stay updated on the latest news?
-
Meginendapunktur rannsóknarinnar var uppfylltur, þegar borin var saman klínísk virkni, öryggi og ónæmingarverkun AVT05 og Simponi (golimumab) í sjúklingum með meðallagi alvarlega eða alvarlega...
-
The confirmatory clinical safety and efficacy study for AVT05, biosimilar candidate to Simponi® and Simponi Aria® (golimumab), met its primary endpoint in patients with moderate to severe rheumatoid...
-
The confirmatory clinical safety and efficacy study for AVT05, biosimilar candidate to Simponi® and Simponi Aria® (golimumab), met its primary endpoint in patients with moderate to severe rheumatoid...
-
Alvotech, in agreement with Teva Pharmaceuticals, has signed an agreement with a strategic partner to bring to the U.S. market the newly FDA approved high-concentration interchangeable biosimilar to...
-
Alvotech, in agreement with Teva Pharmaceuticals, has signed an agreement with a strategic partner to bring to the U.S. market the newly FDA approved high-concentration interchangeable biosimilar to...
-
Langtímasamningur hefur náðst við leiðandi innkaupaaðila lyfja í Bandaríkjunum um sölu- og dreifingu á líftæknilyfjahliðstæðu Alvotech í háum styrk með útskiptanleika við HumiraMeð þessum samningi...
-
Markaðsleyfið er fyrir notkun lyfsins til meðferðar bæði á fullorðnum og börnum Þetta er önnur líftæknilyfjahliðstæða Alvotech sem hlýtur markaðsleyfi í Bandaríkjunum Gert er ráð fyrir að Selarsdi...
-
SELARSDI is approved for both adult and pediatric indications and is the second biosimilar approved under the strategic partnership between Alvotech and Teva SELARSDI is expected to be marketed in the...
-
SELARSDI is approved for both adult and pediatric indications and is the second biosimilar approved under the strategic partnership between Alvotech and Teva SELARSDI is expected to be marketed in the...
-
REYKJAVIK, Iceland, April 03, 2024 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients...